Oncogene, Published online: 05 November 2026; doi:10.1038/s41388-026-04007-0 RHBDL2 promotes cancer stemness and chemoresistance in triple-negative breast cancer through EGFR/PI3K/AKT/mTOR/c-Myc pathway
Dan Wang, Xing Niu, Jingqi Tian, Ruibin Liu, Yuxuan Song, Dingye Zhang et al. RHBDL2 promotes cancer stemness and chemoresistance in triple-negative breast cancer through EGFR/PI3K/AKT/mTOR/c-Myc pathway. // Oncogene. – 2026. – DOI: 10.1038/s41388-026-04007-0. – URL: https://www.nature.com/articles/s41388-026-04007-0
Dan Wang, Xing Niu, Jingqi Tian, Ruibin Liu, Yuxuan Song, Dingye Zhang, Junze Dai, Shenglong Li, & Xudong Zhu (2026). RHBDL2 promotes cancer stemness and chemoresistance in triple-negative breast cancer through EGFR/PI3K/AKT/mTOR/c-Myc pathway. Oncogene. https://doi.org/10.1038/s41388-026-04007-0
Dan Wang, et al. “RHBDL2 promotes cancer stemness and chemoresistance in triple-negative breast cancer through EGFR/PI3K/AKT/mTOR/c-Myc pathway.” Oncogene, 2026. doi:10.1038/s41388-026-04007-0.
@article{Wang2026,
title = {RHBDL2 promotes cancer stemness and chemoresistance in triple-negative breast cancer through EGFR/PI3K/AKT/mTOR/c-Myc pathway},
author = {Wang, Dan and Niu, Xing and Tian, Jingqi and Liu, Ruibin and Song, Yuxuan and Zhang, Dingye and Dai, Junze and Li, Shenglong and Zhu, Xudong},
journal = {Oncogene},
year = {2026},
doi = {10.1038/s41388-026-04007-0},
url = {https://www.nature.com/articles/s41388-026-04007-0}
}